Pandemic Influenza Plan - Questar III

More documents

Recommendations

Info

Appendix 10-A NYSDOH STAFF PRIVATE PROVIDERS REGIONAL BEHAVIORAL LHDs EPI STAFF EMS HEALTH PROVIDERS LAW ENFORCEMENT FUNERAL DIRECTORS, VOLUNTEERS VET MEDICAL EXAMINERS, CORONERS patients X X X X X X Role of the provider X X X X X X Travel history X X X X X X Antiviral treatment regimens X X X X X X X Adverse events X X X X X X Case definition X X X X X X Reporting guidelines X X X X X X X X X VACCINE PROCUREMENT/TREATMENT/USE Overview of vaccine production X X X X X X X Safety monitoring X X X X X X X Vaccine adverse events reporting system (VAERS) X X X X X X X Investigational New Disease protocols X X X X Priority groups X X X X X X X X X X Training of non-licensed persons to administer vaccine X X ANTIVIRAL PROCUREMENT/TREATMENT/USE Overview of treatment vs. prophylaxis X X X X X X X X X X February 7, 2006 4
Appendix 10-A NYSDOH STAFF PRIVATE PROVIDERS REGIONAL BEHAVIORAL LHDs EPI STAFF EMS HEALTH PROVIDERS LAW ENFORCEMENT FUNERAL DIRECTORS, VOLUNTEERS VET MEDICAL EXAMINERS, CORONERS Personal protective equipment X X X X X X X X X X Management of cases of novel influenza strain X X X X X Prioritization hierarchy X X X X X X X X X X Contraindications X X X X X Adverse events monitoring/Med Watch X X X X X Investigational new drug protocols X X X X Practices that reduce development of resistance X X X X X Specifications for tracking/distribution/efficacy/safety of antivirals X X X X X TRAVEL-RELATED DISEASE CONTROL AND COMMUNITY CONTAINMENT Isolation and quarantine at home/special facilities X X X X X X X X X Community containment strategies X X X X X X Awareness level of CDC/WHO travel advisories X X X X X X X X X X Epi investigations and travel history X X X X X X WORKFORCE SUPPORT Stress and traumatic grief X X X X X X X X X X February 7, 2006 5
Page 1 and 2:
February206 Pandemic Plan NewYorkSt
Page 3 and 4:
Introduction Pandemic influenza occ
Page 5 and 6:
example, at this time, it is realis
Page 7 and 8:
Acronyms (cont.) IND IHANS IRB ISHS
Page 9 and 10:
Section 1: Command and Control I. O
Page 11 and 12:
Section 1: Command and Control pers
Page 13 and 14:
February 7, 2006 Appendix 1-A
Page 15 and 16:
Appendix 1-B The Public Health Law
Page 17 and 18:
Appendix 1-B communicable diseases
Page 19 and 20:
Appendix 1-C Management Office or t
Page 21 and 22:
Appendix 1-E Suspension of Public M
Page 23 and 24:
Appendix 1-G A Guide to New York St
Page 25 and 26:
Appendix 1-G health commissioner. P
Page 27 and 28:
Appendix 1-G 8. State Institutions
Page 29 and 30:
Appendix 1-G b. Governor May Invoke
Page 31 and 32:
Appendix 1-G may direct, pursuant t
Page 33 and 34:
Appendix 1-G c. Commissioner of Gen
Page 35 and 36:
Appendix 1-G Designation of emergen
Page 37 and 38:
Appendix 1-G physician’s assistan
Page 39 and 40:
Appendix 1-H Summary of Public Offi
Page 41 and 42:
Section 2: Surveillance and Laborat
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Appendix 2-A • Surveillance Crite
Page 65 and 66:
Appendix 2-A • In New York City,
Page 67 and 68:
NYSDOH Novel Influenza Case Report
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Appendix 2-C to health care provide
Page 75 and 76:
Virus Detection History NYS Lab Num
Page 77 and 78:
Section 3: Healthcare Planning and
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Section 4: Infection Control I. Ove
Page 127 and 128:
Section 4: Infection Control I. Ove
Page 129 and 130:
Section 4: Infection Control A. Bas
Page 131 and 132:
Section 4: Infection Control Drople
Page 133 and 134:
Section 4: Infection Control • Pe
Page 135 and 136:
Section 4: Infection Control o Noti
Page 137 and 138:
Section 4: Infection Control E. Coh
Page 139 and 140:
Section 4: Infection Control If wid
Page 141 and 142:
Section 4: Infection Control • En
Page 143 and 144:
Section 4: Infection Control should
Page 145 and 146:
Section 4: Infection Control Policy
Page 147 and 148:
Section 4: Infection Control o Staf
Page 149 and 150:
Section 4: Infection Control • De
Page 151 and 152:
Section 4: Infection Control • Pr
Page 153 and 154:
Section 4: Infection Control The ma
Page 155 and 156:
Section 4: Infection Control • Up
Page 157 and 158:
Section 4: Infection Control Health
Page 159 and 160:
Appendix 4-A Soiled linen and laund
Page 161 and 162:
Appendix 4-B Respiratory Hygiene/Co
Page 163 and 164:
Section 5: Clinical Guidelines I. O
Page 165 and 166:
Section 5: Clinical Guidelines incu
Page 167 and 168:
Section 5: Clinical Guidelines 1) N
Page 169 and 170:
Section 5: Clinical Guidelines infe
Page 171 and 172:
Section 5: Clinical Guidelines Alth
Page 173 and 174:
Section 5: Clinical Guidelines Infe
Page 175 and 176:
Section 5: Clinical Guidelines •
Page 177 and 178:
Appendix 5-B Clinical Evaluation of
Page 179 and 180:
Appendix 5-C Special Situations and
Page 181 and 182:
Appendix 5-D handling soiled laundr
Page 183 and 184:
DRAFT Appendix 5-E Footnotes to App
Page 185 and 186:
Appendix 5-F February 7, 2006 1
Page 187 and 188:
Appendix 5-F 7. Guidance on the eva
Page 189 and 190:
Appendix 5-H Source: U.S. Departmen
Page 191 and 192:
February 7, 2006 2 Appendix 5-I
Page 193 and 194:
Appendix 5-J Clinical Presentation
Page 195 and 196:
Appendix 5-J diabetes mellitus), re
Page 197 and 198:
Appendix 5-J resistant S. aureus (M
Page 199 and 200:
Appendix 5-K eight patients—all o
Page 201 and 202:
Appendix 5-L Guidelines for Managem
Page 203 and 204:
Appendix 5-L testing should be perf
Page 205 and 206:
Appendix 5-L February 7, 2006 5
Page 207 and 208:
Section 6: Vaccine Procurement, Dis
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Appendix 6-A Vaccine Priority Group
Page 221 and 222:
Appendix 6-B Mass Clinic Planning O
Page 223 and 224:
Appendix 6-C Vaccine and Antiviral
Page 225 and 226:
Appendix 6-C 1. Request Phase The r
Page 227 and 228:
Appendix 6-C 3. Receipt and Sign-of
Page 229 and 230:
Appendix 6-C • Work with local he
Page 231 and 232:
Section 7: Antiviral Medication Pro
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Appendix 7-A Characteristics of Ant
Page 251 and 252:
Appendix 7-B a The drug package ins
Page 253 and 254:
Appendix 7-C 7 HCWs in emergency de
Page 255 and 256:
Section 8: Travel-Related Disease C
Page 257 and 258:
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
Appendix 8-A Home or Community-Base
Page 269 and 270:
Appendix 8-B Contact Identification
Page 271 and 272:
Appendix 8-B • Determine the time
Page 273 and 274:
Appendix 8-C Administrative Data: S
Page 275 and 276:
Appendix 8-D CONTACT DAILY TEMPERAT
Page 277 and 278:
Appendix 8-F Definitions: Intervent
Page 279 and 280: Appendix 8-F facility. No specific
Page 281 and 282: Appendix 8-F • Resources Required
Page 283 and 284: Appendix 8-G Business Pandemic Infl
Page 285 and 286: Appendix 8-G 4. Allocate resources
Page 287 and 288: Appendix 8-H CDC guidelines suggest
Page 289 and 290: Appendix 8-H If I am not masked I
Page 291 and 292: Appendix 8-H NYSDOH Model Influenza
Page 293 and 294: Appendix 8-H I understand that if
Page 295 and 296: Section 9: Communications I. Overvi
Page 297 and 298: Section 9: Communications and commu
Page 299 and 300: Section 9: Communications web pages
Page 301 and 302: Section 9: Communications Local Hea
Page 303 and 304: Section 9: Communications • A JIC
Page 305 and 306: Section 9: Communications backup to
Page 307 and 308: Section 9: Communications • In th
Page 309 and 310: Appendix 9-A Public Health Risk Com
Page 311 and 312: Appendix 9-C New York State Departm
Page 313 and 314: Appendix 9-C PRE-EVENT MESSAGE MAP:
Page 315 and 316: Appendix 9-C PROTECTIVE MESSAGE MAP
Page 317 and 318: Appendix 9-C TREATMENT MESSAGE MAP:
Page 319 and 320: Appendix 9-C BUSINESS CONTINUITY PR
Page 321 and 322: Section 10: Training and Education
Page 327 and 328: Appendix 10-A NYSDOH STAFF PRIVATE
Page 329: Appendix 10-A NYSDOH STAFF PRIVATE
Page 333 and 334: Appendix 10-A NYSDOH STAFF PRIVATE
Page 335 and 336: FACILITY- BASED RNs FACILITY- BASED
Page 341 and 342: Section 11: Workforce Support I. Ov
Page 343 and 344: Section 11: Workforce Support Pande
Page 345 and 346: Section 12: Highly Pathogenic H5N1
Page 347 and 348: Section 12: H5N1 in Non-Human Anima
Page 355 and 356: Section 13: Public Health Preparedn
Page 381 and 382:
Section 13: Public Health Preparedn
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Appendix 13-A NYSDOH Roles Notified
Page 391 and 392:
Appendix 13-B Notifications sent by
Page 393 and 394:
Appendix 13-B HAN posting is used a
Page 395 and 396:
Appendix 13-B notification system t
Page 397 and 398:
Appendix 13-C Overview of the Healt
Page 399 and 400:
Appendix 13-C • Ongoing surveilla
Page 401 and 402:
Table 1. Summary of HERDS Use To da
Page 403 and 404:
Appendix 13-D Commerce Access and A
Page 405 and 406:
Appendix 13-D Table 3. Organization
show all

Pandemic Influenza Plan - Questar III

Create successful ePaper yourself

Delete template?

Save as template?